ERBB2 and breast carcinoma: Among the large number of tumour-associated antigens that can be targeted, HER2 receptor was found to be overexpressed on the cell membrane of various tumour types, including lung, ovarian, stomach, uterine, and especially breast cancers, where 25–30% of cells are HER2-positive.